A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor

Cancer Letters

Volumn 374, Issue 2, 2016, Pages 229-240

  Niesen, Judith ^a   Hehmann Titt, Grit ^b   Woitok, Mira ^a,c   Fendel, Rolf ^a,d   Barth, Stefan ^a,d   Fischer, Rainer ^a,c   Stein, Christoph ^a,d  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b PharmedArtis GmbH   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Chloroquine; EGFR; Granzyme B; Human cytolytic fusion protein; ScFv

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CHLOROQUINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANZYME B; GRANZYME B SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; HYBRID PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; GRANZYME; IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG UPTAKE; EMBRYO; ENZYME ACTIVATION; EPIDERMOID TUMOR; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; STRUCTURE ACTIVITY RELATION; TUMOR BIOPSY; WILD TYPE; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; LYMPHOMA; MALE; PATHOLOGY; TUMOR CELL LINE; U937 CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHLOROQUINE; GRANZYMES; HEK293 CELLS; HUMANS; IMMUNOTOXINS; LYMPHOMA; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; U937 CELLS;

EID: 84975687684     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.020     Document Type: Article

References (56)

1. Antignani A., Fitzgerald D. Immunotoxins: the role of the toxin. Toxins 2013, 5:1486-1502.
2. Hehmann-Titt G., Schiffer S., Berges N., Melmer G., Barth S. Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2013, 2:19-49.
3. Mathew M., Verma R.S. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009, 100:1359-1365.
4. Weidle U.H., Georges G., Brinkmann U. Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon. Cancer Genomics Proteomics 2012, 9:119-133.
5. Schiffer S., Hristodorov D., Mladenov R., Aslanian E., Huhn M., Fischer R., et al. Species-dependent functionality of the human cytolytic fusion proteins granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2013, 2:9-18.
6. Weidle U.H., Tiefenthaler G., Schiller C., Weiss E.H., Georges G., Brinkmann U. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics 2014, 11:25-38.
7. Marcet-Palacios M., Ewen C., Pittman E., Duggan B., Carmine-Simmen K., Fahlman R.P., et al. Design and characterization of a novel human granzyme B inhibitor. Protein Eng. Des. Sel 2015, 28:9-17.
8. Oberoi P., Jabulowsky R.A., Bahr-Mahmud H., Wels W.S. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS ONE 2013, 8:e61267.
9. Oberoi P., Jabulowsky R.A., Wels W. Selective induction of cancer cell death by targeted granzyme B. Antibodies 2013, 2:130-151.
10. Dalken B., Giesubel U., Knauer S.K., Wels W.S. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ 2006, 13:576-585.
11. Stahnke B., Thepen T., Stocker M., Rosinke R., Jost E., Fischer R., et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther 2008, 7:2924-2932.
12. Cao Y., Mohamedali K.A., Marks J.W., Cheung L.H., Hittelman W.N., Rosenblum M.G. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol. Cancer Ther 2013, 12:979-991.
13. Losasso V., Schiffer S., Barth S., Carloni P. Design of human granzyme B variants resistant to serpin B9. Proteins 2012, 80:2514-2522.
14. Schiffer S., Hansen H.P., Hehmann-Titt G., Huhn M., Fischer R., Barth S., et al. Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer J. 2013, 3:e106.
15. Schiffer S., Rosinke R., Jost E., Hehmann-Titt G., Huhn M., Melmer G., et al. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Int. J. Cancer 2014, 135:1497-1508.
16. Niesen J., Stein C., Brehm H., Hehmann-Titt G., Fendel R., Melmer G., et al. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J. Cancer Res. Clin. Oncol 2015, 141:2079-2095.
17. Niesen J., Brehm H., Stein C., Berges N., Pardo A., Fischer R., et al. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. J. Cancer Res. Clin. Oncol 2014, 141:1049-1061.
18. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
19. Ganti R., Skapek S.X., Zhang J., Fuller C.E., Wu J., Billups C.A., et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol 2006, 19:1213-1220.
20. Tebbutt N., Pedersen M.W., Johns T.G. Targeting the ERBB family in cancer: couples therapy. Nat. Rev. Cancer 2013, 13:663-673.
21. Yewale C., Baradia D., Vhora I., Patil S., Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013, 34:8690-8707.
22. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol 2002, 20:1s-13s.
23. Bruell D., Stocker M., Huhn M., Redding N., Kupper M., Schumacher P., et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int. J. Oncol 2003, 23:1179-1186.
24. Bruell D., Bruns C.J., Yezhelyev M., Huhn M., Muller J., Ischenko I., et al. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int. J. Mol. Med 2005, 15:305-313.
25. Hristodorov D., Mladenov R., Pardo A., Pham A.T., Huhn M., Fischer R., et al. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br. J. Cancer 2013, 109:1570-1578.
26. Koefoed K., Steinaa L., Soderberg J.N., Kjaer I., Jacobsen H.J., Meijer P.J., et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3:584-595.
27. Toporkiewicz M., Meissner J., Matusewicz L., Czogalla A., Sikorski A.F. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int. J. Nanomedicine 2015, 10:1399-1414.
28. Sasaki K., Tsuno N.H., Sunami E., Tsurita G., Kawai K., Okaji Y., et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10:370.
29. Wu M. Enhancement of immunotoxin activity using chemical and biological reagents. Br. J. Cancer 1997, 75:1347-1355.
30. Fuchs H., Bachran C., Flavell D. Diving through membranes: molecular cunning to enforce the endosomal escape of antibody-targeted anti-tumor toxins. Antibodies 2013, 2:209-235.
31. Cizeau J., Grenkow D.M., Brown J.G., Entwistle J., MacDonald G.C. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J. Immunother 2009, 32:574-584.
32. Brehm H., Niesen J., Mladenov R., Stein C., Pardo A., Fey G., et al. A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues. Cancer Lett 2014, 352:228-235.
33. Mladenov R., Hristodorov D., Cremer C., Hein L., Kreutzer F., Stroisch T., et al. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. Int. J. Cancer 2015, 137:2729-2738.
34. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8:E532-E551.
35. Thorpe S.J., Turner C., Heath A., Feavers I., Vatn I., Natvig J.B., et al. Clonal analysis of a human antimouse antibody (HAMA) response. Scand. J. Immunol 2003, 57:85-92.
36. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
37. Alewine C., Hassan R., Pastan I. Advances in anticancer immunotoxin therapy. Oncologist 2015, 20:176-185.
38. Kreitman R.J. Chimeric fusion proteins - Pseudomonas exotoxin-based. Curr. Opin. Investig. Drugs 2001, 2:1282-1293.
39. Shan L., Liu Y., Wang P. Recombinant immunotoxin therapy of solid tumors: challenges and strategies. J. Basic Clin. Med 2013, 2:1-6.
40. Tur M.K., Neef I., Jost E., Galm O., Jager G., Stocker M., et al. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J. Immunother 2009, 32:431-441.
41. Brehm H., Hristodorov D., Pardo A., Mladenov R., Niesen J., Fischer R., et al. Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer Lett 2015, 365:149-155.
42. Redman J.M., Hill E.M., AlDeghaither D., Weiner L.M. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol 2015, 67:28-45.
43. Bremer E., Samplonius D.F., van Genne L., Dijkstra M.H., Kroesen B.J., de Leij L.F., et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem 2005, 280:10025-10033.
44. Weidle U.H., Tiefenthaler G., Georges G. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genom. Proteom 2014, 11:67-79.
45. Rosenblum M.G., Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr. Pharm. Des 2009, 15:2676-2692.
46. Mohamedali K.A., Cao Y., Cheung L.H., Hittelman W.N., Rosenblum M.G. The functionalized human serine protease granzyme B/VEGF(1)(2)(1) targets tumor vasculature and ablates tumor growth. Mol. Cancer Ther 2013, 12:2055-2066.
47. Kapelski S., de Almeida M., Fischer R., Barth S., Fendel R. Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein. Antimicrob. Agents Chemother 2015, 59:669-672.
48. Gehrmann M., Doss B.T., Wagner M., Zettlitz K.A., Kontermann R.E., Foulds G., et al. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J. Immunol. Methods 2011, 371:8-17.
49. Liu Y., Cheung L.H., Hittelman W.N., Rosenblum M.G. Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol. Cancer Ther 2003, 2:1341-1350.
50. Kurschus F.C., Kleinschmidt M., Fellows E., Dornmair K., Rudolph R., Lilie H., et al. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 2004, 562:87-92.
51. Lorentsen R.H., Fynbo C.H., Thogersen H.C., Etzerodt M., Holtet T.L. Expression, refolding, and purification of recombinant human granzyme B. Protein Expr. Purif 2005, 39:18-26.
52. Jabulowsky R.A., Oberoi P., Bahr-Mahmud H., Dalken B., Wels W.S. Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFalpha fusion protein. Bioconjug. Chem 2012, 23:1567-1576.
53. Haile Y., Carmine-Simmen K., Olechowski C., Kerr B., Bleackley R.C., Giuliani F. Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo. J. Neuroinflammation 2015, 12:157.
54. Zhang X., Sawyer G.J., Dong X., Qiu Y., Collins L., Fabre J.W. The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. J. Gene Med 2003, 5:209-218.
55. Sandvig K., van Deurs B. Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther 2005, 12:865-872.
56. Gattenlohner S., Jorissen H., Huhn M., Vincent A., Beeson D., Tzartos S., et al. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J. Biomed. Biotechnol 2010, 2010:187621.